Targeting a kinase? Find out how BMG LABTECH microplate readers measure interaction with kinases, kinase activities and kinase inhibitors in high throughput.
Drugs acting on a therapeutic target have to be identified out of libraries of thousands to millions of compounds. Due to the large amount of tests necessary for a screen, they are mainly conducted in 384 and 1536 well plates to minimize reaction volumes per sample.
Speed and sensitivity are key requirements for high-throughput screening microplate readers. A 1536 well microplate needs to be measured in seconds, maximally a few minutes. Furthermore, the fast measurement of 10 µl or even lower volume samples need to be very precise and stable to clearly identify hits from a vast number of compounds. In addition, the reader needs to be reliable, as errors occurring during a screen result in repetitions, loss of time, reagents and consequently money. The PHERAstar FSX masters all these requirements in all detection modes, making it popular in screening facilities.
For screening assay development and testing, it is not necessary to block the dedicated screening reader, the CLARIOstar Plus is the perfect addition to develop and characterize an assay before transitioning to high throughput.
Search our Resources section for information about specific applications, literature citations, videos, blog articles and many other publications. Many of the resources provided are associated with current and previous instrument models and versions.
Binding kinetics: high throughput assay for kinase inhibitorsKrumm A (1) , Georgi V (2) , Schiele F (2) , Fernández-Montalván A (2), (1) BMG LABTECH GmbH , (2) Bayer AG, Drug Discovery, Pharmaceuticals, Berlin, Germany, 06/2020
Dual Channel Kinetic assays for detecting ligand bias at GPCRsPaul Tewson (1) , Scott Martinka (1) , Kevin M. Harlen (1) , Thom Hughes (1) , Anne Marie Quinn (1) , Sam R.J. Hoare (2) , Carl Peters (3), (1) Montana Molecular, Bozeman, MT , (2) Pharmechanics, Owego, NY , (3) BMG LABTECH Inc., NC, USA, 11/2019
Analyze binding kinetics with HTRFNicolas Pierre , Thomas Roux, Cisbio Bioassays, Codolet, France, 05/2019
NanoBRET™ assay quantitatively evaluates VEGF binding to the VEGFR2 in real-time in living cellsKilpatrick LE (1) , Friedman-Ohana R (2) , Alcobia DC (1) , Riching K (2) , Peach CJ (1) , Wheal AJ (1) , Briddon SJ (1) , Robers MB (2) , Zimmerman K (2) , Machleidt T (2) , Wood KV (2) , Woolard J (1) , Hill SJ (1), (1) Division of Physiology, Pharmacology and Neuroscience, University of Nottingham, UK , (2) Promega Corporation, Madison, WI, USA, 01/2018
CRISPR/Cas9 genome-edited cells express nanoBRET-donor that monitors protein interaction and traffickingCarl White (1,2) , Ethan See (1,2) , Kevin Pfleger (1,2,3), (1) Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research, Australia , (2) Centre for Medical Research, The University of Western Australia, Australia , (3) Dimerix Limited, Nedlands, Australia, 01/2018
Monoclonal antibody drugs – a history of success and a bright future!
High-throughput screening (HTS)
Lab Automation – Pipetting many thousands of samples by hand is awful
The identification and characterisation of autophagy inhibitors from the published kinase inhibitor setsRead article
Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidateRead article
Eur J Med Chem
Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonistsRead article
D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson\'s diseaseRead article
J. Clin. Invest.
CRISPR-Mediated Protein Tagging with Nanoluciferase to Investigate Native Chemokine Receptor Function and Conformational ChangesRead article
Cell Chem Biol